Stock Events

Stock Events

Amplify Treatments Testing and Advancements 

$19.17
11
+$0+0% Thursday 19:53

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

27
JUN
Dividend Ex
Estimated
 
28
JUN
Dividend Payment
Estimated
 
20
SEP
Dividend Ex
Estimated
 
22
SEP
Dividend Payment
Estimated
 

Dividends

0%Dividend Yield
Mar 26
$0.09
Dec 25
$0.09
Sep 25
$0.09
Jun 25
$0.09
Mar 25
$0.09
10Y Growth
N/A
5Y Growth
21.18%
3Y Growth
2.91%
1Y Growth
-25%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GERM. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap10.61B
Moderna, Inc. focuses on mRNA-based therapies, directly competing in the biotech space for treatments and vaccines, similar to GERM's focus on advanced treatments.
BioNTech
BNTX
Mkt Cap24.99B
BioNTech SE specializes in personalized immunotherapies, which overlaps with GERM's advancements in treatment technologies.
Pfizer
PFE
Mkt Cap140.15B
Pfizer Inc. has a broad portfolio in healthcare, including treatments and vaccines that compete with GERM's product offerings.
Novavax
NVAX
Mkt Cap1.36B
Novavax, Inc. is involved in the development of vaccines, competing in the same space as GERM's focus on treatment and prevention.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, Inc. is known for its antiviral drugs, directly competing with GERM's advancements in treatments.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals, Inc. works on biopharmaceuticals, including treatments that could rival GERM's innovative therapies.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie Inc. operates in the pharmaceuticals sector, with a focus on advanced therapies that could compete with GERM's product line.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson has a diverse healthcare portfolio, including pharmaceuticals that could compete with GERM's treatments.
AMGEN
AMGN
Mkt Cap160.66B
Amgen Inc. focuses on human therapeutics, which could compete with GERM's advancements in treatment technologies.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca PLC has a wide range of pharmaceutical products, including treatments and vaccines that could compete with GERM's offerings.

About

Miscellaneous
Investment Trusts/Mutual Funds
The index tracks the performance of U.S.-listed equity securities or depositary receipts of companies that (i) perform research, development, and commercialization of treatments or vaccines for infectious diseases or (ii) engage in the research, development, manufacturing, and provision of biological tests for patients. The fund invests at least 80% of its total assets in the component securities of the index. The fund is non-diversified.
Show more...
CEO
Country
US
ISIN
US0321085815

Listings

0 Comments

Share your thoughts

FAQ

What is Amplify Treatments Testing and Advancements stock price today?▼
The current price of GERM is $19.17 USD — it has increased by +0% in the past 24 hours. Watch Amplify Treatments Testing and Advancements stock price performance more closely on the chart.
What is Amplify Treatments Testing and Advancements stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Amplify Treatments Testing and Advancements stocks are traded under the ticker GERM.
Does Amplify Treatments Testing and Advancements pay dividends?▼
Yes, GERM dividends are paid quarterly. The last dividend per share was 0.09 USD. As of today, Dividend Yield (FWD)% is 0%.
In which sector is Amplify Treatments Testing and Advancements located?▼
Amplify Treatments Testing and Advancements operates in the Other sector.
When did Amplify Treatments Testing and Advancements complete a stock split?▼
Amplify Treatments Testing and Advancements has not had any recent stock splits.